Analysis of Clinical Pathological Features and Prognosis in Young Patients with Diffuse Large B Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2019.03.026
- Author:
Shu FANG
1
;
Sha-Sha ZHAO
2
,
3
;
Cheng-Ying ZHU
2
,
3
;
Nan YANG
1
;
Fei-Yan WANG
2
,
3
;
Li-Li WANG
1
;
Wen-Rong HUANG
2
,
4
;
Chun-Ji GAO
2
,
5
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing 100853, China.
2. Department of Hematology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing 100853, China
3. Nankai University School of Medicine, Tianjin 300071,China.
4. E-mail: huangwr301@163.com.
5. E-mail: gaochunji@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse;
Multivariate Analysis;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(3):802-808
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical pathological features of the patients with diffuse large B cell lymphoma (DLBCL) and their prognostic factors.
METHODS:The prognosis of the clinical pathological features and their influence on prognosis of 177 patients diagnosed as DLBCL at the first visit from January 2013 to May 2017 in our hospital were analyzed retrospectively.
RESULTS:The univariate analysis showed that overall survival (OS) and progression-free survival (PFS) were associated with later Ann Arbor stage (Ⅲ-Ⅳ) ( P＜0.01, P＜0.05), high performance status (ECOG score 2-4) (P＜0.01, P＜0.05), extranodal involvement ＞1 (P＜0.01, P＜0.05), elevated LDH level (P＜0.01, P＜0.05). B symptom (P＜0.05) and elevated β2-MG level (P＜0.05) also influenced OS. COX multivariate analysis showed that the elevated β2-MG level (P＜0.05) and later stage (Ⅲ-Ⅳ) (P＜0.05) have an independent influence on OS, later stage (Ⅲ-Ⅳ) (P＜0.05) also independently influenced PFS. The patients with high aaIPI score (2-3) and bone marrow involvement before treatment had poor OS (P＜0.01, P＜0.01) and PFS (P＜0.05, P＜0.01).
CONCLUSION:Elevated β2-MG level can independently influence OS, and later stage (Ⅲ-Ⅳ) can independently influence both OS and PFS. High aaIPI score (2-3) and bone marrow involvement before treatment have an inferior influence on OS and PFS.
